Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma.
Pancreatic ductal adenocarcinoma
diagnostic biomarker
interleukin-2 (il-2)
macrophage migration inhibitory factor (mif)
prognostic biomarker
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Various reports have pointed out the potential of cytokines as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDA). Nonetheless, the evidence is contradictory and the role of chronic inflammation and relationship between circulatory and corresponding tumoral cytokine levels remain elusive. Utilizing a broad array of cytokines, we identified two opposing parameters: serum levels of interleukin 2 (IL2) and macrophage migration inhibitory factor (MIF) are diagnostic and prognostic factors. While low IL2 levels are associated with PDA, they also relate to a favorable prognosis of patients. In contrast, high MIF levels are associated with PDA and simultaneously related to an unfavorable outcome. MIF levels are associated with the intratumoral density of M2 macrophages (CD163
Identifiants
pubmed: 34408923
doi: 10.1080/2162402X.2021.1962135
pii: 1962135
pmc: PMC8366538
doi:
Substances chimiques
Interleukin-2
0
Macrophage Migration-Inhibitory Factors
0
Intramolecular Oxidoreductases
EC 5.3.-
MIF protein, human
EC 5.3.2.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1962135Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
None declared.
Références
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
BMC Cancer. 2005 Jul 06;5:73
pubmed: 16000172
Curr Opin Pharmacol. 2009 Aug;9(4):411-8
pubmed: 19589727
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Cell. 2016 Nov 3;167(4):1125-1136.e8
pubmed: 27814509
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
J Immunol. 2018 Jun 15;200(12):3926-3933
pubmed: 29728511
Anal Quant Cytol Histol. 2010 Dec;32(6):333-40
pubmed: 21456345
Nat Immunol. 2017 Jul 19;18(8):851-860
pubmed: 28722709
Front Oncol. 2021 May 13;11:677609
pubmed: 34055645
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
PLoS One. 2009 Nov 16;4(11):e7847
pubmed: 19924291
Cancer Cell. 2016 Apr 11;29(4):587-601
pubmed: 27070705
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
N Engl J Med. 2006 Feb 9;354(6):610-21
pubmed: 16467548
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
Br J Clin Pharmacol. 2020 Sep;86(9):1836-1848
pubmed: 32207164
Oncoimmunology. 2013 Apr 1;2(4):e24116
pubmed: 23734335
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Immunol. 2015 Sep 1;195(5):2343-52
pubmed: 26209628
J Clin Lab Anal. 2010;24(4):256-61
pubmed: 20626020
Int J Cancer. 2014 Jun 1;134(11):2646-55
pubmed: 24615168
Hepatology. 2007 Jul;46(1):6-8
pubmed: 17596866
Oncol Rep. 2018 Nov;40(5):2628-2636
pubmed: 30226561
PLoS One. 2016 May 12;11(5):e0154016
pubmed: 27170998
Oncoimmunology. 2016 Apr 25;5(6):e1163462
pubmed: 27471638
Pancreas. 2018 Sep;47(8):958-966
pubmed: 30074526
Int J Cancer. 2013 Feb 15;132(4):785-94
pubmed: 22821831
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Nat Rev Immunol. 2003 Oct;3(10):791-800
pubmed: 14502271
Clin Chem Lab Med. 2013 Jul;51(7):1459-66
pubmed: 23492572
Trends Immunol. 2015 Dec;36(12):763-777
pubmed: 26572555
Br J Cancer. 2014 Jan 7;110(1):183-8
pubmed: 24201751
Clin Cancer Res. 2002 Dec;8(12):3755-60
pubmed: 12473586
Clin Cancer Res. 2011 Feb 15;17(4):678-89
pubmed: 21325295
J Gastroenterol Hepatol. 2004 Feb;19(2):182-6
pubmed: 14731128
J Immunol. 2013 Mar 15;190(6):2984-93
pubmed: 23390297
Cancer Causes Control. 2006 May;17(4):403-9
pubmed: 16596292